Loading...

BioNexus Gene Lab Corp.

BGLC•NASDAQ
Healthcare
Medical - Diagnostics & Research
$5.64
$0.010(0.18%)

BioNexus Gene Lab Corp. (BGLC) Stock Overview

Explore BioNexus Gene Lab Corp.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.0/100

Key Financials

Market Cap10.1M
P/E Ratio-3.41
EPS (TTM)$-1.64
ROE-0.36%
Fundamental Analysis

AI Price Forecasts

1 Week$3.83
1 Month$3.42
3 Months$0.00
1 Year Target$0.25

BGLC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioNexus Gene Lab Corp. (BGLC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 51.70, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.25.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.41 and a market capitalization of 10.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-2.26%
5-Day Change
-13.20%
1-Month Change
-40.55%
3-Month Change
563.61%
6-Month Change
417.90%
Year-to-Date (YTD) Change
443.86%
1-Year Change
236.43%
3-Year Change
-89.18%
5-Year Change
-91.78%
All-Time (Max) Change
-91.78%

Contact Information

https://www.bionexusgenelab.com
60 1 2212 6512
Tower B, Vertical Business Suite, Kuala Lumpur, 59200

Company Facts

30 Employees
IPO DateJan 8, 2021
CountryMY
Actively Trading

Frequently Asked Questions

;